AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that its partner Life Molecular Imaging (LMI) has received Fast Track Designation for the Tau positron emission tomography (PET) diagnostic, [18F]PI-2620, from the U.S. Food and Drug Administration (FDA) in three neurodegenerative conditions.
– PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s partner, LMI
– This Fast Track designation applies across Alzheimer’s disease, progressive supranuclear palsy, and corticobasal degeneration
– Follows two previous Fast Track designations for ACI-35.030 and ACI-24.060 active immunotherapies
– Affirms AC Immune’s leadership and commitment to bringing precision medicine to the management of neurodegenerative diseases